The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia - Milan 2023

Pneumonia

Chair(s): Michal Shteinberg, Oriol Sibila Vidal

Session type: Oral presentation

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia

Hsu-Yuan Chen

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Efficacy of a respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults with co-existing cardiorespiratory conditions

Alberto Papi

Replay

Poster

Abstract

Slides

CheXED artificial intelligence to detect radiographic pneumonia in urgent care clinic patients.

Nathan Dean

Replay

Poster

Abstract

Slides

Individualized treatment rule (ITR) for early steroid use in hospitalized patients with community acquired pneumonia (CAP)

Yewande Odeyemi

Replay

Poster

Abstract

Slides

Molecular diagnostic resistance patterns in the BALF of hospitalised patients with pneumonia

Andrei Darie

Replay

Poster

Abstract

Slides

Diagnostic behaviours among patients with community acquired pneumonia in the age of CoVid-19

Phoebe Hazenberg

Replay

Poster

Abstract

Slides

Epidemiology of community-acquired pneumonia (CAP) in Europe during the COVID-19 pandemic preliminary results of PNEUMO study Europe

Lisa Hessels

Replay

Poster

Abstract

Slides

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia

Hsu-yuan Chen

Replay

Poster

Abstract

Slides

Quality of life following CAP hospitalization: preliminary results from the PNEUMO study Europe

Lisa Hessels

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}